Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E7046 是一种口服有效的特异性 EP4拮抗剂,IC50值为 13.5 nM,Ki 值为 23.14 nM,具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 163 | 现货 | ||
5 mg | ¥ 328 | 现货 | ||
10 mg | ¥ 479 | 现货 | ||
25 mg | ¥ 892 | 现货 | ||
50 mg | ¥ 1,570 | 现货 | ||
100 mg | ¥ 2,330 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 349 | 现货 |
产品描述 | E7046 is a specific, orally bioavailable EP4 antagonist (IC50: 13.5 nM, Ki: 23.14 nM), exhibiting anti-tumor activities. |
靶点活性 | EP4:13.5 nM, EP4:23.14 nM (Ki) |
体外活性 | Through selective EP4 antagonism, E7046 reverses the immunosuppressive effects of PGE2 on activation and differentiation of human myeloid cells [1]. |
体内活性 | E7046 (150 mg/kg) inhibits the growth of multiple syngeneic tumor models. The blockade of EP4 signaling promotes anti-tumor DC differentiation and slows tumor growth in mice. E7046 treatment reduces the growth or even rejected established tumors in vivo in a manner dependent on both myeloid and CD8C T cells [1]. In the CT-26 tumor model, the E7046/RT combination causes the anti-tumor memory response of 9 animals. In the 4T1 model, the combination of E7046 and RT also produces significantly better tumor growth inhibition activity compared with each treatment alone. The combination significantly improves survival by inhibiting the subsequent spontaneous lung metastasis of 4T1 tumors [2]. |
分子量 | 483.4 |
分子式 | C22H18F5N3O4 |
CAS No. | 1369489-71-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (206.87 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0687 mL | 10.3434 mL | 20.6868 mL | 51.717 mL |
5 mM | 0.4137 mL | 2.0687 mL | 4.1374 mL | 10.3434 mL | |
10 mM | 0.2069 mL | 1.0343 mL | 2.0687 mL | 5.1717 mL | |
20 mM | 0.1034 mL | 0.5172 mL | 1.0343 mL | 2.5859 mL | |
50 mM | 0.0414 mL | 0.2069 mL | 0.4137 mL | 1.0343 mL | |
100 mM | 0.0207 mL | 0.1034 mL | 0.2069 mL | 0.5172 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
E7046 1369489-71-3 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor Inhibitor E 7046 inhibit E-7046 inhibitor